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Background: Antibiotic therapy can select for small colony variants of Staphylococcus aureus that are more
resistant to antibiotics and can result in persistent infections, necessitating the development of more effective
antimicrobial strategies to combat small colony variant infections. Photodynamic therapy is an alternative
treatment approach which utilises light in combination with a light-activated antimicrobial agent to kill bacteria
via a non-specific mechanism of action. In this study, we investigated whether the combination of 665 nm laser
light and the light-activated antimicrobial agent methylene blue was able to successfully kill S. aureus small colony
variants. S. aureus and isogenic stable small colony variant were exposed to varying doses (1.93 to 9.65 J/cm2) of
665 nm laser light in the presence of varying concentrations (1 to 20 μM) of methylene blue.
Results: The combination of 665 nm laser light and methylene blue was found to be an effective strategy for the
killing of small colony variants. At the highest light dose (9.65 J/cm2) and methylene blue concentration (20 μM) tested,
the number of viable bacteria decreased by approximately 6.9 log10 for the wild type and approximately 5 log10 for the
small colony variant.
Conclusions: These results suggest that photodynamic therapy has potential for use in the treatment of superficial
infections caused by small colony variants of S. aureus and supports further research in this field.
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Small colony variants (SCVs) of Staphylococcus aureus
are a naturally-occurring subpopulation often associated
with chronic antibiotic exposure [1]. S. aureus SCVs are
characterized by their slow growth rate and small colony
size relative to the parent strain, and can cause persist-
ent infections in the lungs of cystic fibrosis patients and
infections of skin, bone and implanted devices [2].
S. aureus SCVs are clinically important due to their
reduced susceptibility to antibiotics. SCVs are commonly
auxotrophs for hemin, menadione or thymidine, resulting
in electron transport chain defects and consequently
reduced membrane potential and reduced uptake of
cationic antibiotics [3]. Resistance to cell wall–active
antibiotics such as β-lactams occurs due to the slow
growth rate and reduced cell wall metabolism of SCVs [4].* Correspondence: Sean.Nair@ucl.ac.uk
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reproduction in any medium, provided the orGiven their persistent nature and their selection by
and resistance to conventional antibiotics, there is a
need to identify effective therapies for SCV infections.
One potential novel strategy is photodynamic therapy,
which utilizes light in combination with a light-activated
antimicrobial agent, known as a photosensitiser, to gen-
erate toxic reactive oxygen species such as free radicals
and singlet oxygen. Upon irradiation, the photosensitiser
undergoes a transition from a low energy ground state
to a higher energy triplet state, which can then react with
biomolecules to produce free radicals or with molecular
oxygen to produce highly reactive singlet oxygen. These
reactive oxygen species can oxidise many biological
structures and kill bacteria via several mechanisms, most
notably by damaging the cytoplasmic membrane [5].
There are several potential advantages of light-activated
antimicrobial agents over conventional antimicrobial
therapy. Firstly, collateral damage to the host or host
microbiota is limited due to the very short half-life and
diffusion distance of the reactive oxygen species produced.
Secondly, resistance is unlikely as reactive oxygen speciesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing proteins, lipids and nucleic acids. We have previously
shown that light-activated antimicrobial agents such as
methylene blue and tin (IV) chlorin e6 are effective against
meticillin-sensitive S. aureus, epidemic meticillin-resistant
S. aureus (MRSA), community-acquired MRSA and van-
comycin intermediate S. aureus (VISA) [6,7], and are
effective for decolonizing wound infections in vivo [8].
However given that most light activated antimicrobials
are cationic compounds and that SCVs have a reduced
membrane potential which makes them more resistant
to cationic antimicrobials it is possible that such light
activated antimicrobials would not be effective at killing
SCVs. Therefore the aim of this study was to determine
the capacity of the cationic light activated antimicrobial
agent methylene blue in combination with 665 nm laser
light to kill S. aureus SCVs.
Results and discussion
As mentioned small colony variants of S. aureus have
been reported to have increased resistance to conventional
antimicrobials such as aminoglycosides. In this study we
determined that the minimum inhibitory concentration of
the aminoglycoside kanamycin against the hemB and
menD small colony variants was 8-fold higher (128 μg/ml)
than the isogenic parent strains (16 μg/ml).
The hemB SCV and its isogenic parent were both
found to be susceptible to photodynamic killing using
methylene blue and 1.93 J/cm2 of 665 nm laser light in
a methylene blue concentration-dependent manner
(Figure 1). Neither laser light nor photosensitiser alone
had any effect on bacterial viability (data not shown).
The menD SCV and its wild-type parent were alsoFigure 1 Number of viable bacteria recovered following
exposure to 1.93 J/cm2 of 665 nm laser light and different
concentrations of methylene blue. The clear bars represent
recovery of the wild type strain LS-1 and the grey bars the isogenic
hemB SCV. Error bars represent the standard deviation from the
mean. **P < 0.01, ***P < 0.001 (ANOVA).susceptible to photodynamic killing by methylene blue
(20 μM) and 1.93 J/cm2 of 665 nm laser light, with
reductions in cell viability of 3.5 log10 and 4.1 log10,
respectively (data not shown). Increasing the light dose
was found to significantly increase the killing of both
the hemB SCV and its parent strain; the highest light
dose examined (9.65 J/cm2) resulted in reductions in viable
cells of approximately 6.9 log10 and 5 log10 respectively
(Figure 2). There was no significant difference between
the kills observed for both strains when a light dose of
9.65 J/cm2 was used for the experiments.
Small colony variants of S. aureus represent a serious
challenge to clinicians treating infections caused by these
microorganisms [2] due to the increased antibiotic re-
sistance and persistent infections that are characteristic
of SCVs [1,3,4]. It would therefore be advantageous to
develop a therapeutic strategy with a differing mode of
action to those antibiotics for which lower susceptibility is
observed. We have previously shown that light-activated
antimicrobial agents, which have a non-specific mode
of action, are highly effective at killing S. aureus [6-8].
To investigate the capacity of the light-activated anti-
microbial agent methylene blue in combination with
laser light for eradicating SCVs of S. aureus, we used
stable hemin (hemB mutant) and menadione (menD
mutant) auxotrophic SCVs of S. aureus, which we
found to have an 8-fold increase in resistance to the
aminoglycoside kanamycin. Our results demonstrate
that the combination of methylene blue and laser light
of 665 nm effectively kills S. aureus SCVs, suggesting
that photodynamic therapy could be a promising alter-
native therapy for SCV infections. Selection for SCVs
and development of resistance are unlikely due to the
non-specific mechanism of action of photodynamicFigure 2 Number of viable bacteria recovered following
exposure to methylene blue and different doses of 665 nm
laser light. The clear bars represent recovery of the wild type strain
LS-1 and the grey bars the isogenic hemB SCV. Error bars represent
the standard deviation from the mean. ***P < 0.001 (ANOVA).
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antibiotic treatment. One potential limitation to the
effectiveness of photodynamic therapy is that in some
infections SCVs enter the cytoplasm of host cells [3]. In
such cases it is likely that higher photodynamic therapy
doses would be required resulting in some collateral
damage to host tissue. One possible way to overcome
this problem would be to develop photosensitisers that
target the intracellular bacteria specifically.
Photodynamic therapy has been proposed for the
decontamination of the anterior nares in cases of MRSA
carriage [6,8,9]. Cases of infections associated with con-
comitant colonisation of the anterior nares by S. aureus
small colony variants have been reported in the litera-
ture [10-12]; therefore, photodynamic therapy may also
be of use as a decontamination strategy in cases where
the anterior nares represent a reservoir of SCVs.
Conclusion
In conclusion, we propose that photodynamic therapy has
potential for use in the treatment of superficial infections
by SCVs of S. aureus and for nasal decolonisation.
Methods
The S. aureus strains used were the laboratory strain
8325–4 and an isogenic mutant, D1324, disrupted in
menD [13], (a gift from Professor Richard Proctor), and
LS-1 and its isogenic mutant disrupted in hemB [14]. S.
aureus was maintained by subculture on blood agar
(Oxoid Ltd, UK) incubated aerobically at 37°C. For
experimental purposes, bacteria were inoculated into
Brain Heart Infusion broth and cultured aerobically for
16 hrs at 37°C, with shaking at 200 rpm. Cultures were
then centrifuged and resuspended in an equal volume
of PBS and the optical density adjusted to 0.05 at 600 nm,
corresponding to approximately 1 × 107 colony forming
units (CFU) per mL. Methylene blue (C16H18ClN3S.
3H2O) and all other reagents were purchased from
Sigma-Aldrich (UK).
The MIC of kanamycin was determined according to
the CLSI microbroth dilution. A Periowave™ diode laser
(Ondine Biomedical Inc., Canada), which emits light
with a wavelength of 665 nm was used throughout the
study. The power output of the laser was 73 mW and
the beam diameter was 1.7 cm. The laser system was set
up so that the laser beam covered the entire well of a
microtitre plate in which experiments were performed.
To examine the effect of photosensitiser concentration
on the photodynamic killing of S. aureus SCVs, methy-
lene blue was diluted in PBS to give final concentrations
of 1, 5, 10 and 20 μM. Methylene blue (50 μL) was
added to an equal volume of the inoculum in triplicate
wells of a sterile, flat-bottomed 96-well plate and irradi-
ated with 665 nm laser light with an energy density of1.93 J/cm2, with stirring. Three additional wells containing
50 μL of methylene blue and 50 μL of the bacterial sus-
pension were kept in the dark to assess the toxicity of
the photosensitiser alone. To assess the toxicity of laser
light alone, 50 μL PBS was added to 50 μL of the inoculum
in a further six wells, three of which were irradiated
with laser light and the remaining three kept in the
dark. Following irradiation/dark incubation, samples
were serially diluted 10-fold in PBS and plated onto 5%
horse blood agar plates in triplicate. The plates were
incubated aerobically overnight at 37°C, following which
the surviving CFU/mL were enumerated by viable
counting. Experiments were performed three times in
triplicate.
To examine the effect of laser light dose on the photo-
dynamic killing of the SCVs, methylene blue was diluted
in PBS to give a final concentration of 20 μM. Experi-
ments were performed as described above, but bacteria
were irradiated with 1.93 J/cm2, 3.86 J/cm2 or 9.65 J/cm2
of 665 nm laser light, with stirring. Following irradi-
ation/dark incubation, viable bacteria were enumerated
as described as above.
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